Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The portfolio includes a range of projects from first in human drug trials through to large Phase III clinical studies. Studies assess interventions including radiotherapy, drug combinations and novel imaging techniques.

Our current portfolio is divided into 3 categories:
  • Early phase.
  • Radiotherapy and Imaging.
  • Data Rich Trials.

Prospective Clinical Trials

Active Clinical Trials

In Follow-up

  • ATOM: Pre-operative window of opportunity study of the effects of atovaquone on hypoxia in non-small cell lung carcinoma
  • CAMELLIA: A Phase I dose escalation trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Haematological Malignancies
  • DOC-MEK: A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma.  To determine the efficacy and tolerability of the combination of the selective MEK inhibitor AZD6244 with docetazel in patients with wild-type BRAF metastatic melanoma.
  • SPARC: Stereotactic Body Radiotherapy (SBRT) pre-operatively for pancreatic cancer: A Phase I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer.
  • WBRTWhole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – A randomised Phase III trial.  

Completed

  • 6MPA Phase II Clinical trial in patients with known BRCA Defective Tumours.
  • ART: Anal squamous cell carcinoma: Investigation of functional imaging during Chemoradiotherapy (CRT)
  • AspECT: A Phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia.
  • BKM120: A CR-UK phase I study of BKM120 in patients with non-small cell lung cancer (NSCLC) receiving thoracic radiotherapy.
  • CHOP-OR: Phase II single arm multi-centre NCRI feasibility study of CHOP combined with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome. 
  • COGRandomised phase III trial of gefitinib 500mg once daily versus placebo in oesophageal cancer progressing after chemotherapy.
  • DATACAP: Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring: A Pilot Study of Optimal Dose Scheduling of Capecitabine for Patients with Metastatic Colorectal or Metastatic Breast Cancer.
  • DEBIOC: A Phase I dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma
  • EnROL: Conventional versus laparoscopic surgery for colorectal cancer within an enhanced programme.
  • FOXFIRE: An open-label randomised phase III trial of 5-Fluorouracil, OXaliplatin and Folinic acid +/- Interventional Radio-Embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer.
  • FRONTIER: An open-labelled study to characterise Fluciclovine (18F) uptake measured by positron emission tomography in breast cancer
  • LINES: Eurosarc Trial of Linsitinib in advanced Ewing Sarcoma
  • MEMOS: 
  • Mobile Phone Project: Using GPRS mobile phone technology for managing symptoms associated with chemotherapy for colon cancer
  • OXO-PCR-01: A Single-Centre Prospective Phase 0 Translational Study for Predicting Response of High Grade Serous Ovarian Cancers to Paclitaxel Chemotherapy
  • PACMEL: A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma
  • QUASAR 2: A multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer.
  • RADVAN: A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases.
  • RHYTHM-1: Modulation of Radiotherapy according to HYpoxia: exploiting changes in the Tumour Microenvironment to improve outcome in rectal cancer
  • SCOT: Short Course Oncology Treatment - A study of adjuvant chemotherapy in colorectal cancer by the  CACTUS and OCTO groups.
  • SONATINA: A Phase II Multi-Centre Randomised Controlled Study Of Nelfinavir Addition to Radiotherapy Treatment In Neo-Adjuvant Therapy for Rectal Cancer.
  • TARDOX: A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin from Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients with Primary or Secondary Liver Tumours.
  • VICTOR: Post-treatment stage of a Phase III, randomised, double blind, placebo-controlled study of rofecoxib (VIOXX®) in colorectal cancer patients following potentially curative therapy.

On this page